[go: up one dir, main page]

UY24697A1 - Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa - Google Patents

Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa

Info

Publication number
UY24697A1
UY24697A1 UY24697A UY24697A UY24697A1 UY 24697 A1 UY24697 A1 UY 24697A1 UY 24697 A UY24697 A UY 24697A UY 24697 A UY24697 A UY 24697A UY 24697 A1 UY24697 A1 UY 24697A1
Authority
UY
Uruguay
Prior art keywords
protease inhibitors
vhi
produce hiv
methods
intermediate products
Prior art date
Application number
UY24697A
Other languages
English (en)
Inventor
Srinivasan Babu
P Remarchuk Travis
C Borer Bennett
J Szendroi Robert
R Whitten Kathleen
K Busse Juliette
F Albizati Kim
Original Assignee
Agouron Pharmaceuticals Inc Y Japan Tobacco Inc
Agouron Pharma
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals Inc Y Japan Tobacco Inc, Agouron Pharma, Japan Tobacco Inc filed Critical Agouron Pharmaceuticals Inc Y Japan Tobacco Inc
Publication of UY24697A1 publication Critical patent/UY24697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibidotes VHI-proteasa, particularmente Sulfatos cíclicos, de fórmula general 6 (figura 1), no limitante, o una sal o solvato farmacéuticamente aceptable del mismo, donde R2 es arilo y R3 es arilo o alquilo. Estos inhibidores de la VHI-proteasa inhiben o bloquean la actividad biológica de la enzima VHI-proteasa, causando que la replicación del virus VHI , estos compuestos pueden ser preparados mediante los métodos novedosos de la presente invención, usando los agentes intermedios novedosos de la invención. Por ejemplo se incluye un esquema de síntesis de base libre de neolfinavir a partir del ácido (2S,3S)-(-)-tartárico a través de la ruta de azido alcohol.
UY24697A 1996-09-05 1997-09-05 Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa UY24697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/708,607 US5705647A (en) 1996-09-05 1996-09-05 Intermediates for making HIV-protease inhibitors

Publications (1)

Publication Number Publication Date
UY24697A1 true UY24697A1 (es) 1997-10-21

Family

ID=24846475

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24697A UY24697A1 (es) 1996-09-05 1997-09-05 Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa

Country Status (16)

Country Link
US (1) US5705647A (es)
EP (1) EP0931071B1 (es)
JP (2) JP2001501183A (es)
AR (1) AR009532A1 (es)
AT (1) ATE397591T1 (es)
AU (1) AU4247097A (es)
CA (1) CA2264725A1 (es)
CO (1) CO4900044A1 (es)
DE (1) DE69738751D1 (es)
ES (1) ES2306461T3 (es)
ID (1) ID17012A (es)
IN (1) IN183739B (es)
MY (1) MY132553A (es)
UY (1) UY24697A1 (es)
WO (1) WO1998009952A1 (es)
ZA (1) ZA977868B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) * 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2286013C (en) * 1997-04-10 2003-07-15 F. Hoffmann-La Roche Ag Process for making a butylthio-isoquinoline and intermediates therefor
US6130348A (en) 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
WO1999048371A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
US20050049242A1 (en) * 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
WO2003012126A2 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
KR100695861B1 (ko) * 2003-05-08 2007-03-19 화이자 인코포레이티드 Ｈｉｖ-프로테아제 억제제 합성에 유용한 중간체 및 그의제조 방법
EP2631981B1 (en) 2010-10-22 2016-08-17 Mitsui Chemicals, Inc. Cyclic sulfate compound, non-aqueous electrolyte solution containing same, and lithium secondary battery

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
HUT60282A (en) * 1991-02-08 1992-08-28 Sankyo Co Process for producing new beta-amino-alpha-hydroxycarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5256783A (en) * 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
AU3278293A (en) * 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
DE69300043T2 (de) * 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
DK0641325T3 (da) * 1992-05-21 2001-04-17 Monsanto Co Inhibitorer af retroviral protease
DK0810209T3 (da) * 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
ES2103488T3 (es) * 1992-08-25 1997-09-16 Searle & Co N-(alcanoilamino-2-hidroxipropil)sulfonamidas utiles como inhibidores de proteasas retrovirales.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
DE69738751D1 (de) 2008-07-17
ATE397591T1 (de) 2008-06-15
ID17012A (id) 1997-11-27
ZA977868B (en) 1998-03-30
ES2306461T3 (es) 2008-11-01
JP2009040788A (ja) 2009-02-26
CO4900044A1 (es) 2000-03-27
IN183739B (es) 2000-04-01
MY132553A (en) 2007-10-31
AR009532A1 (es) 2000-04-26
EP0931071B1 (en) 2008-06-04
US5705647A (en) 1998-01-06
CA2264725A1 (en) 1998-03-12
EP0931071A1 (en) 1999-07-28
WO1998009952A1 (en) 1998-03-12
AU4247097A (en) 1998-03-26
JP2001501183A (ja) 2001-01-30

Similar Documents

Publication Publication Date Title
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
PT88255A (pt) Processo para a preparacao de derivados do indole
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
HUP0400694A2 (hu) A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
CY1107473T1 (el) Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις
EA200401053A1 (ru) Оксо-азабициклические соединения
KR950011444A (ko) 갈란타민 유도체, 이의 제조방법 및 약제로서의 이의 용도
AR006833A1 (es) Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
CA2216664A1 (fr) Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
MA27130A1 (fr) Nouveau procede de synthese de derives de l'acide (2s,3as,7as)-1-[(s)-alanyl]-octahydro- 1h-indole-2-carboxylique et application a la synthese du perindopril
FI803264L (fi) 2-hydroxialkyl-3,4,5-trihydroxipiperidiner foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA199800155A1 (ru) Новое соединение
EA200100969A1 (ru) Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции
AR027578A1 (es) Derivados de indano
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CA2404700A1 (fr) Nouveau procede de synthese de esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril
EA199600007A3 (ru) Новые трициклические производные, способ их получения, способы получения оптически активных или рацемических колхицина и тиоколхицина, их аналогов или производных с использованием трициклических соединений и промежуточные продукты синтеза
PT84680B (pt) Processo para a preparacao de derivados de 1,5-benzotiazepina e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170905